Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...

DF sales are likely to grow 15% YoY to Rs 1,400 crore driven by the integration of the Sanofi portfolio ... 12.5% YoY led by strong growth in Gastro/Derma/Vaccines and in-licensing opportunities.